Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Experts are expecting strong performance driven by the strong demand of Lilly's blockbuster drugs, particularly the diabetes franchise. However, there are also concerns about potential headwinds from